Endocrinology · 1993
DCCT (Diabetes Control and Complications Trial)
Before the DCCT, the link between blood glucose control and diabetic complications was contested. Observational data supported it, and animal models were consistent, but no large randomized trial had directly tested whether achieving near-normal glycemia in type 1 diabetes would prevent retinopathy, neuropathy, or nephropathy. Some endocrinologists remained skeptical; others worried that aggressive insulin therapy simply caused dangerous hypoglycemia without meaningful clinical gain. The question had practical stakes for every patient with type 1 diabetes.
The Diabetes Control and Complications Trial enrolled 1,441 patients at 29 centers in the United States and Canada between 1983 and 1989. Half were randomized to intensive insulin therapy, with the goal of keeping blood glucose as close to normal as possible using multiple daily injections or insulin pumps; the other half continued conventional management with one or two daily injections and less frequent monitoring. The trial was designed to run for years, and it did: participants were followed for a mean of 6.5 years before the Data and Safety Monitoring Board stopped it early because the magnitude of benefit had become too large to justify continuing the control arm.
Intensive therapy cut the risk of retinopathy by 76% in patients without preexisting retinopathy, and slowed progression by 54% in those who already had early changes. Clinical neuropathy fell by 60%, and microalbuminuria, the earliest marker of diabetic kidney disease, was reduced by 39%. HbA1c averaged 7.2% in the intensive group versus 9.1% in the conventional arm. The difference in glycemic exposure was real, and the complications data tracked it with a consistency that made the findings persuasive even to skeptics.
The cost was concrete: patients in the intensive arm experienced two to three times the rate of severe hypoglycemia requiring assistance. This finding shaped how physicians applied the DCCT results. Tight control became the target, but it was modulated by individual risk for hypoglycemia, which varied with age, awareness status, comorbidities, and social circumstances. The trial's findings were not simply a mandate to push HbA1c as low as possible; they defined a goal and identified a hazard.
Follow-up through the Epidemiology of Diabetes Interventions and Complications study, known as EDIC, found that the microvascular benefits persisted for at least a decade after the randomized trial ended, even as glycemic differences between the two original groups narrowed over time. Intensive therapy during the DCCT years also reduced cardiovascular events in the long-term EDIC follow-up. The trial made HbA1c-guided management the standard for type 1 diabetes worldwide, and its methodology set the model for subsequent outcome trials in both type 1 and type 2 disease.
Key People
- The DCCT Research Group — 29-center US and Canadian collaborative that conducted the trial
- David Nathan — Principal investigator and Massachusetts General Hospital co-chair
- Oscar Crofford — NIDDK program director who championed funding for the DCCT
N Engl J Med. 1993
Related landmarks
- 1994 · Discovery of Leptin (Endocrinology)
- 1998 · UK Prospective Diabetes Study (UKPDS 33) (Endocrinology)
- 1982 · Recombinant Human Insulin (Humulin) Approval (Endocrinology)
- 2008 · ACCORD (Endocrinology)